Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NUVB logo NUVB
Upturn stock ratingUpturn stock rating
NUVB logo

Nuvation Bio Inc (NUVB)

Upturn stock ratingUpturn stock rating
$3.15
Last Close (24-hour delay)
Profit since last BUY34.04%
upturn advisory
Consider higher Upturn Star rating
BUY since 39 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/15/2025: NUVB (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $7.5

1 Year Target Price $7.5

Analysts Price Target For last 52 week
$7.5 Target price
52w Low $1.54
Current$3.15
52w High $4.09

Analysis of Past Performance

Type Stock
Historic Profit 12.02%
Avg. Invested days 37
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.07B USD
Price to earnings Ratio -
1Y Target Price 7.5
Price to earnings Ratio -
1Y Target Price 7.5
Volume (30-day avg) 7
Beta 1.37
52 Weeks Range 1.54 - 4.09
Updated Date 09/15/2025
52 Weeks Range 1.54 - 4.09
Updated Date 09/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.38

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Revenue by Geography

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1315.72%

Management Effectiveness

Return on Assets (TTM) 20.17%
Return on Equity (TTM) -44.84%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 524778347
Price to Sales(TTM) 74.87
Enterprise Value 524778347
Price to Sales(TTM) 74.87
Enterprise Value to Revenue 36.56
Enterprise Value to EBITDA 2.23
Shares Outstanding 341272992
Shares Floating 231047778
Shares Outstanding 341272992
Shares Floating 231047778
Percent Insiders 19.03
Percent Institutions 66.74

ai summary icon Upturn AI SWOT

Nuvation Bio Inc

stock logo

Company Overview

overview logo History and Background

Nuvation Bio Inc. was founded in 2018 by David Hung. It focuses on developing therapies for unmet medical needs, particularly in oncology. The company aims to in-license and develop promising drug candidates.

business area logo Core Business Areas

  • Oncology Drug Development: Focuses on developing therapies for various cancers, including both solid tumors and hematologic malignancies.

leadership logo Leadership and Structure

David Hung is the founder and CEO. The company has a board of directors and a management team overseeing research, development, and operations.

Top Products and Market Share

overview logo Key Offerings

  • NUV-868: A BDCR-resistant and brain-penetrant inhibitor of HER2. It is in clinical trials for HER2-altered solid tumors. There is currently no significant market share for this product as it's in development stage. Competitors include companies developing other HER2 inhibitors, such as AstraZeneca (AZN) and Roche (RHHBY).
  • NUV-1511: A novel oral selective replication-competent oncolytic virus engineered to selectively replicate within cancer cells, leading to tumor lysis and immune activation. It is in clinical trials for advanced solid tumors. There is currently no significant market share for this product as it's in development stage. Competitors include companies developing other oncolytic viruses, such as Amgen (AMGN).

Market Dynamics

industry overview logo Industry Overview

The oncology market is a large and rapidly growing market driven by increasing cancer incidence and improved treatment options. There is intense competition among pharmaceutical and biotechnology companies.

Positioning

Nuvation Bio aims to differentiate itself by focusing on in-licensing and developing novel therapies that address unmet needs in specific cancer subtypes. Its competitive advantage lies in its focused approach and experienced leadership team.

Total Addressable Market (TAM)

The global oncology market is projected to reach trillions of dollars. Nuvation Bio is positioned to capture a portion of this market by developing targeted therapies for specific cancer indications.

Upturn SWOT Analysis

Strengths

  • Experienced leadership team
  • Focused development strategy
  • Promising drug candidates in pipeline
  • Strong financial backing

Weaknesses

  • Limited number of products in pipeline
  • Reliance on successful clinical trials
  • High cash burn rate
  • Relatively new company

Opportunities

  • Expansion of product pipeline through in-licensing
  • Positive clinical trial results
  • Strategic partnerships with larger pharmaceutical companies
  • Approval of drug candidates by regulatory agencies

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Changes in reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • AZN
  • RHHBY
  • AMGN
  • MRTX

Competitive Landscape

Nuvation Bio faces intense competition from established pharmaceutical companies with larger pipelines and greater resources. Its success depends on its ability to differentiate its therapies and execute its clinical development strategy.

Growth Trajectory and Initiatives

Historical Growth: Nuvation Bio's growth is primarily reflected in the advancement of its clinical pipeline. No revenue to date.

Future Projections: Future growth depends on the successful development and commercialization of its drug candidates. Analyst estimates vary widely depending on clinical trial outcomes.

Recent Initiatives: Advancing NUV-868 and NUV-1511 through clinical trials, exploring new in-licensing opportunities.

Summary

Nuvation Bio is a clinical-stage biopharmaceutical company with promising oncology assets. Its success is contingent upon positive clinical trial results and regulatory approvals. While the company has a strong leadership team and financial backing, it faces significant competition and inherent risks associated with drug development.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Nuvation Bio Inc

Exchange NYSE
Headquaters New York, NY, United States
IPO Launch date 2020-08-24
Founder, President, CEO & Chairman Dr. David T. Hung M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 278
Full time employees 278

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.